Boehringer Ingelheim Pharmaceuticals (BIP) investor relations material

Business performance and growth

• Net sales reached EUR 27.8 billion in 2025, a 7.3% increase, with both Human Pharma and Animal Health contributing to growth.

• Human Pharma net sales were EUR 22.7 billion (+7.4%), driven by Jardiance (EUR 8.8 billion, +8.7%) and Ofev (EUR 3.8 billion, +5%).

• Animal Health achieved EUR 4.9 billion in sales (+6.5%), with NexGard leading at EUR 1.4 billion (+8.5%).

• BioXcellence business grew over 19%, supporting both internal and external pharma production.

• Investments in infrastructure spanned four continents, including major projects in Japan, Germany, and the U.S.

R&D and innovation

• R&D investment rose to EUR 6.4 billion (23% of revenues), with Human Pharma at EUR 5.8 billion (27%) and Animal Health at over EUR 500 million (11%).

• Two new molecular entities, HERNEXEOS and JASCAYD, were launched, marking significant pipeline progress.

• Over 80 projects are in development across four therapeutic areas, with 2/3 of assets having first-in-class potential.

• Six new pivotal phase III trials were initiated, strengthening the late-stage pipeline.

• AI and digital technologies are integrated across the value chain, including drug design and production.

Animal Health trends and pipeline

• Growth in Animal Health driven by rising pet populations, increased owner investment, and livestock demand.

• Addressed major disease outbreaks (bluetongue, avian influenza, foot-and-mouth) through collaboration and innovation.

• New products include VAXXITEK H5 vaccine and emergency use approvals for screwworm treatments.

• Pipeline advances include AI-powered diagnostics for canine cardiology and new therapies for equine insulin dysregulation.

• Virus-like particle technology is being developed for chronic pet diseases.